NCT06759090 - Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

June 15, 2028

Conditions

Metastatic Pancreatic Carcinoma

Interventions

DRUG

Metronomic capecitabine

Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal;

DRUG

Camrelizumab

Camrelizumab: a PD-1 inhibitor, 200 mg, intravenous injection once every 2 weeks;

DRUG

Apatinib Mesylate Tablets

Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with water within 30 minutes after a meal.

Trial Locations (1)

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Zhejiang University

OTHER